Modern rheumatology · 2026
Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: A subgroup analysis of the MARS study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ishii Tomonori, Kunishige Hideaki, Yoshida Mitsuhiro, Hayashi Etsuko, Komatsubara Masaki, Alfonso-Cristancho Rafael, Howarth Peter
Аннотация
OBJECTIVES: Evaluate the long-term safety and effectiveness of mepolizumab in subgroups of patients with eosinophilic granulomatosis with polyangiitis, including: disease duration, oral corticosteroid (OCS) use, relapse, worsening or new-onset symptoms, anti-neutrophil cytoplasm antibodies (ANCA) status, and immunosuppressive therapy use.
METHODS: Data from the 96-week MARS study in Japan were analysed for patients receiving mepolizumab for ≥96 weeks, focusing on adverse events (AEs), clinical symptoms, average daily OCS dose, and relapse.
RESULTS: OCS exposure decreased in most subgroups, particularly in the ANCA negative subgroup. Patients on higher average OCS doses (>7.5 mg/day vs ≤7.5 mg/day, during the observation period) experienced more AEs, including infection-related AEs and clinical symptoms, and higher relapse rates. No relapses were observed in patients on an average dose of 0.0 mg/day OCSs. Reduced OCS use was associated with improved clinical outcomes, particularly in patients who remained relapse-free.
CONCLUSIONS: Mepolizumab was effective regardless of eosinophilic granulomatosis with polyangiitis duration, ANCA status, or immunosuppressant use. Higher OCS doses were linked to more AEs, clinical symptoms, and relapses compared to lower doses. In relapse-free patients, continued mepolizumab use led to fewer AEs, lower OCS doses, and improved symptoms.
METHODS: Data from the 96-week MARS study in Japan were analysed for patients receiving mepolizumab for ≥96 weeks, focusing on adverse events (AEs), clinical symptoms, average daily OCS dose, and relapse.
RESULTS: OCS exposure decreased in most subgroups, particularly in the ANCA negative subgroup. Patients on higher average OCS doses (>7.5 mg/day vs ≤7.5 mg/day, during the observation period) experienced more AEs, including infection-related AEs and clinical symptoms, and higher relapse rates. No relapses were observed in patients on an average dose of 0.0 mg/day OCSs. Reduced OCS use was associated with improved clinical outcomes, particularly in patients who remained relapse-free.
CONCLUSIONS: Mepolizumab was effective regardless of eosinophilic granulomatosis with polyangiitis duration, ANCA status, or immunosuppressant use. Higher OCS doses were linked to more AEs, clinical symptoms, and relapses compared to lower doses. In relapse-free patients, continued mepolizumab use led to fewer AEs, lower OCS doses, and improved symptoms.